ESSA PHARMA INC (EPIX)
CA29668H7085 - Common Stock
ESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
/CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the...
ESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
/PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for...
Oversold Conditions For ESSA Pharma (EPIX)
ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS
/PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX), a clinical stage pharmaceutical company focused on developing novel therapies for the...
ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS
/CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX), a clinical stage pharmaceutical company focused on developing novel therapies for the...
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2023
/CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the...
ESSA Pharma to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
/CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the...
ESSA Pharma to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
/PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for...
ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers Symposium
Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in patients with mCRPC Phase 2 dose...
ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers Symposium
Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in patients with mCRPC Phase 2 dose...
EPIX Stock Earnings: ESSA Pharma Beats EPS for Q4 2023
EPIX stock results show that ESSA Pharma beat analyst estimates for earnings per share the fourth quarter of 2023.
EPIX Stock Earnings: ESSA Pharma Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips ESSA Pharma (NASDAQ:EPIX) just reported results for the fourth quarter of 2023....
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2023
/PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company, focused on developing novel therapies for...
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2023
/CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company, focused on developing novel therapies for the...
ESSA Pharma director Franklin Berger buys common shares worth ~$133.3K (NASDAQ:EPIX)
ESSA Pharma director Franklin Berger purchased approximately 23.3K common shares at a price of $5.73/share, amounting to around $133.3K.
ESSA Pharma to Present at the Piper Sandler 35th Annual Healthcare Conference
/CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the...
ESSA Pharma says Berger bought 76.5K shares in co (NASDAQ:EPIX)
Franklin Berger purchases 76.5K shares of ESSA Pharma at $5.35-$5.99 per share, bringing his total holdings to 760.9K shares.
ESSA Pharma to Present at the Jefferies London Healthcare Conference
/CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the...
ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 30th Annual Prostate Cancer Foundation Scientific Retreat
/PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for...
ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 30th Annual Prostate Cancer Foundation Scientific Retreat
/CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the...
ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the European Society of Medical Oncology 2023 Congress
/PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for...
ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the European Society of Medical Oncology 2023 Congress
/CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the...
ESSA Pharma files for $200M mixed shelf offering - filing (NASDAQ:EPIX)
ESSA Pharma (EPIX) disclosed in a Securities and Exchange filing on Tuesday a prospectus for a mixed shelf offering to raise up to $200 million. Under the offering, the company may...
ESSA Pharma Announces Initiation of Phase 2 Study Evaluating Masofaniten (EPI-7386) in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
/CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the...
ESSA Pharma Insiders Establish Automatic Securities Disposition Plans
/CNW/ - ESSA Pharma Inc. (Nasdaq: EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the...
ESSA Pharma Insiders Establish Automatic Securities Disposition Plans
/PRNewswire/ - ESSA Pharma Inc. (Nasdaq: EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the...
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2023
Completion of the Phase 1 EPI-7386 combination study with Xtandi® (enzalutamide) expected in the third calendar quarter of 2023 followed by initiation of the...
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2023
Completion of the Phase 1 EPI-7386 combination study with Xtandi® (enzalutamide) expected in the third calendar quarter of 2023 followed by initiation of the...
ESSA Pharma Appoints Lauren Merendino to its Board of Directors
/CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the...
ESSA Pharma Appoints Lauren Merendino to its Board of Directors
/PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for...
ESSA Pharma to Present at 2023 Jefferies Healthcare Conference
/CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the...